To elucidate the correlation between EZH2 expression and survival outcomes in different tumor patients, we examined six prominent cancer types (liver hepatocellular carcinoma [LIHC], kidney renal clear cell carcinoma [KIRC], breast invasive carcinoma [BRCA], colon adenocarcinoma [COAD], lung squamous cell carcinoma [LUSC], stomach adenocarcinoma [STAD]) within the cancer genome atlas (TCGA). Here, EZH2 is linked to gastric adenocarcinoma.